NF2 and Vestibular schwannoma: Lapatinib showed objective activity in 4 out of 17 patients with NF2-related progressive vestibular schwannoma in a phase II trial [92], whereas erlotinib was not effective in a retrospective series with 11 NF2 patients [93].